TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01221207

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Contact Cast
Description: A total contact cast (TCC) is a special cast technique that is used to take the pressure and shear stress off the ulcer to assist in the healing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Instant Total Contact Cast (ITCC)
Description: The instant total contact cast (ITCC) is a technique that uses the removable cast walker, but secures it so it cannot be removed between clinic visits and evaluation by the subject or the physician.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Removable Cast Walker (RCW)
Description: The removable cast walker (RCW) is a commercial product that is similar to a cast. It is secured with Velcro straps around the foot and leg and it is also effective at removing the pressure and shear stress on the foot.
Study: NCT00074308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02164266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6799477
Description: Daily oral administration of RO6799477
Study: NCT01779492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycontine CR 10mg
Description: twice a day
Study: NCT04392648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-573
Description: TAK-573 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-573
Description: TAK-573 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-573
Description: TAK-573 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-573
Description: TAK-573 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-573
Description: TAK-573 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-573
Description: TAK-573 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide capsules orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide capsules orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib injection subcutaneously.
Study: NCT02358226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soccer League (SL)
Description: Participants will be invited to attend soccer practice in the late afternoons, roughly 2-3 times per week. Competitive games will be held on Saturdays so that friends and family may attend. Using a mobile phone application, coaches will regularly record information on participants' arrival and departure times, sportsmanship, volunteering in the community, the results of saliva tests for drugs and alcohol. The SL intervention arm will last for one year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soccer League/Vocational Training (SL-V)
Description: In addition to the SL intervention, participants will gain access to vocational training. The Vocational Training will take place through the Silulo or Zenzele programs based in Khayelitsha for a period of 6 months. These programs offer practical and market-related training in computer skills, woodwork, or welding. The SL-V intervention arm will last for one year; with six months dedicated to soccer and six months dedicated to vocational training.
Study: NCT02021630

Intervention type: OTHER
Intervention: Outcomes
Description: No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
Study: NCT01134302

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Norwood management strategy
Description: Norwood palliation will be performed as per current clinical practice at The Hospital for Sick Children.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid Strategy
Description: Hybrid palliation will be performed as per current clinical practice at The Hospital for Sick Children.~The 'Hybrid' management strategy utilizes catheter-based and non-open heart surgical procedures in the neonatal period to stabilize the neonate.10 The majority of the reconstruction is thereby deferred to 4-6 months of age, at which time the second stage procedure including an aortic arch reconstruction is performed. The third stage procedure (Fontan) is identical between Norwood and Hybrid strategies.
Study: NCT04115215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise (PE)
Description: This arm includes 10 sessions of multi-component exercise sessions (including aerobic, resistance, flexibility, dual-tasking) of 1 hour/week of functional group exercise, directed to foster empowerment for subsequent continuation of exercise in community-dwelling older adults referred by primary care to a geriatrician and an expert physical therapist. Participants will receive a leaflet with instructions to perform five strength-based exercises and instructors will recommend participants to perform the exercises and walk at least 15 minutes daily.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise (PE)
Description: This arm includes 10 sessions of multi-component exercise sessions (including aerobic, resistance, flexibility, dual-tasking) of 1 hour/week of functional group exercise, directed to foster empowerment for subsequent continuation of exercise in community-dwelling older adults referred by primary care to a geriatrician and an expert physical therapist. Participants will receive a leaflet with instructions to perform five strength-based exercises and instructors will recommend participants to perform the exercises and walk at least 15 minutes daily.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial current stimulation (tCS)
Description: This arm includes 1 application/week for 10 weeks during PE, through an adapted commercial helmet. Transcranial current stimulation (tCS) is a neural stimulation technique based on electrical stimulation of selected parts of the brain with direct or alternated electrical current (tDCS or tACS) of very low intensity of 1,5 milliamps (mA), using one or more electrodes placed on the skull. tCS is non-invasive (no surgical procedures) and it is painless, as applied in the proposed protocols.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants of similar profile, randomized to the control group, will undergo weekly 30 minutes educational sessions on healthy aging, including relevant aspects of nutrition, self-care, physical activity, plus measurement of blood pressure, heart rate and peripheral oxygen Hb saturation. These participants will be offered to join the PE program after the 6-months follow-up (end of the study).
Study: NCT03727789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FACT Complex-targeting Curaxin CBL0137
Description: Given IA
Study: NCT02021630

Intervention type: OTHER
Intervention: Outcomes
Description: No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.

Intervention type: OTHER
Intervention: Outcomes
Description: No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
Study: NCT02908750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine tablet dosing
Description: Fexofenadine (P-gp substrate) 120mg taken once daily on Days 1 in Treatment Period 1 and Day 1 and Day 39 in Treatment Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertininb tablet dosing
Description: Osimertininb 80 mg taken once daily on Day 1 and Days 4 to 41 in Treatment Period 2
Study: NCT01571011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CURB
Description: The intervention is made up of 14 internet modules based on behavioral activation, cognitive behavioral therapy, and interpersonal psychotherapy as well as motivational interviews in the primary care setting (to enhance behavior change). It is suggested that an adolescent navigates through 2 modules a week. The motivational interviews with the physicians occur directly before and after the adolescent is exposed to the website (at baseline and 3 months) in the providers office. The parents of the enrolled adolescents are also invited to navigate through their own, 3 module, parent internet program.
Study: NCT02499796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hygrovent Gold
Study: NCT04392648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib injection subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets orally.
Study: NCT02395614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine irrigation
Description: - 0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles will be used to irrigate one breast pocket. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
Study: NCT02499796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated and moisture exchanger (HME)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated humidifier (HH)
Study: NCT02176954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test A
Description: Test A is a new 1-piece ostomy appliance developed by Coloplast A/S

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test A
Description: Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
Study: NCT02395614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triple antibiotic irrigation
Description: -triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.~80 mg of gentamicin in 500 mL of NS. If the patient is allergic to either component - the allergen will not be used in the solution - to irrigate one breast pocket
Study: NCT00851929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: ambrisentan 5 mg/day for month month, then 10 mg/day for 3 additional months
Study: NCT00225381

Intervention type: DEVICE
Intervention: Humidity sensor
Description: Small conventional anesthesia T piece including tiny 2 thermometer inside

Intervention type: DEVICE
Intervention: Humidity sensor
Description: Small conventional anesthesia T piece including tiny 2 thermometer inside
Study: NCT02176954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test A
Description: Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
Study: NCT00934128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vapotherm
Description: Deliver air in and out of the lungs, warmed, filtered for bacteria, and then delivered through the nose using a tube under the nostrils.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vapotherm
Description: Deliver air in and out of the lungs, warmed, filtered for bacteria, and then delivered through the nose using a tube under the nostrils.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIPAP
Description: Air given through a mask, and amount can be set to different levels allowing more air in and out of lungs without using as much effort as regular breathing.
Study: NCT02176954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test A
Description: Test A is a new 1-piece ostomy appliance developed by Coloplast A/S

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test A
Description: Test A is a new 1-piece ostomy appliance developed by Coloplast A/S

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test A
Description: Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
Study: NCT04392648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets orally.
Study: NCT00225381

Intervention type: DEVICE
Intervention: A mixing chamber (bymixer)
Description: 2 mixing chambers (bymixers) composed of 2 arms where one arm serves as a mixing (passive) arm for the measurement of mixed gas fraction. The bymixer is made of conventional anesthesia supplies and does not influence dead space nor circuit resistance.
Study: NCT02176954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test B
Description: Test B is a new 1-piece ostomy appliance developed by Coloplast A/S
Study: NCT00934128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIPAP
Description: Air given through a mask, and amount can be set to different levels allowing more air in and out of lungs without using as much effort as regular breathing.
Study: NCT01091012

Intervention type: DRUG
Group type: OTHER
Intervention: Sildenafil 20mg oral vs Sildenafil 10mg intravenous
Description: 2 arms to comparation: Sildenafil 20mg oral vs intravenous Sildenafil 10mg
Study: NCT02176954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test B
Description: Test B is a new 1-piece ostomy appliance developed by Coloplast A/S

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test B
Description: Test B is a new 1-piece ostomy appliance developed by Coloplast A/S

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test B
Description: Test B is a new 1-piece ostomy appliance developed by Coloplast A/S

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test B
Description: Test B is a new 1-piece ostomy appliance developed by Coloplast A/S

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test B
Description: Test B is a new 1-piece ostomy appliance developed by Coloplast A/S

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Two comparators will be used: Moderma Flex (Hollister) or Confidence Natural drainable (Salts).These product are commercially available.~Subjects will be randomized into one of twelwe arms. Data will be analyzed by pooling the two comparators, Moderma Flex and Confidence Natural, Drainable, why six arms are displayed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Two comparators will be used: Moderma Flex (Hollister) or Confidence Natural drainable (Salts).These product are commercially available.~Subjects will be randomized into one of twelwe arms. Data will be analyzed by pooling the two comparators, Moderma Flex and Confidence Natural, Drainable, why six arms are displayed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Two comparators will be used: Moderma Flex (Hollister) or Confidence Natural drainable (Salts).These product are commercially available.~Subjects will be randomized into one of twelwe arms. Data will be analyzed by pooling the two comparators, Moderma Flex and Confidence Natural, Drainable, why six arms are displayed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Two comparators will be used: Moderma Flex (Hollister) or Confidence Natural drainable (Salts).These product are commercially available.~Subjects will be randomized into one of twelwe arms. Data will be analyzed by pooling the two comparators, Moderma Flex and Confidence Natural, Drainable, why six arms are displayed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Two comparators will be used: Moderma Flex (Hollister) or Confidence Natural drainable (Salts).These product are commercially available.~Subjects will be randomized into one of twelwe arms. Data will be analyzed by pooling the two comparators, Moderma Flex and Confidence Natural, Drainable, why six arms are displayed.
Study: NCT03222401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg/kg single infusion of F598
Description: 1 mg/kg single infusion of F598
Study: NCT02176954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Two comparators will be used: Moderma Flex (Hollister) or Confidence Natural drainable (Salts).These product are commercially available.~Subjects will be randomized into one of twelwe arms. Data will be analyzed by pooling the two comparators, Moderma Flex and Confidence Natural, Drainable, why six arms are displayed.
Study: NCT03225001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN XT transcatheter valve, Model 9300TFX
Description: Edwards SAPIEN XT THV system Model 9300TFX with the associated delivery systems.
Study: NCT03145675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin (Staged-dose PCI Group)
Description: Enoxaparin 0.5+0.25 mg/kg administered intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin (Single-dose PCI Group)
Description: Enoxaparin 0.75 mg/kg administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin (High-dose Group)
Description: Enoxaparin 0.75 mg/kg administered intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin (Standard-dose Group)
Description: Enoxaparin 0.5 mg/kg administered intravenously.
Study: NCT02023931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broccoli Sprout Extract (BSE)
Description: 1. The first regimen will involve oral delivery and ingestion of 600 μmole doses of glucoraphanin-rich BSE (GRR-BSE), and will represent systemic delivery of sulforaphane to oral mucosa, due to the necessity to metabolize GRR-BSE in the gut.~2. The second regimen will involve oral delivery and ingestion of 100 μmole doses of sulforaphane-rich BSE (SFR-BSE), which will represent a combination of systemic and topical delivery to the oral mucosa.~3. The third regimen will isolate topical exposure of the oral mucosa to sulforaphane. Participants will swish, hold, then spit 100 μmole doses of SFR-BSE. This regimen (SFR-BSE(T)) will theoretically isolate the pharmacodynamic impact of topical exposure of the oral mucosa to sulforaphane.
Study: NCT02965417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004
Description: Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).
Study: NCT03222401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg/kg single infusion of F598
Description: 3 mg/kg single infusion of F598
Study: NCT02665221

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Treatment Arm
Description: Participants randomized to the control group will have no topical treatment at the injection site of the first full dose of Plegridy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Preparation H arm
Description: Preparation H (phenylephrine) treatment first full dose incidence injection site reaction.
Study: NCT02252354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TAK-385 Oral Solution
Description: TAK-385 oral radiolabelled solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385 Tablets
Description: TAK-385 tablets 2 X 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TAK-385 Solution for Intravenous Infusion
Description: TAK-385 intravenous (IV) radiolabelled solution
Study: NCT04077554

Intervention type: GENETIC
Intervention: gene expression
Description: determination of VEGF gene expression, VEGF gene polymorphism and serum leptin concentration

Intervention type: GENETIC
Intervention: gene expression
Description: determination of VEGF gene expression, VEGF gene polymorphism and serum leptin concentration
Study: NCT03710980

Intervention type: DEVICE
Intervention: Oximeter
Description: Participants breathe a controlled gas mixture to induce several reduced oxygen states while oximeter measurements are taken for comparison to corresponding arterial blood draw samples to assess oximeter accuracy.
Study: NCT03222401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg/kg single infusion of F598
Description: 10 mg/kg single infusion of F598
Study: NCT01279681

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study: NCT01583842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 124I-Metaiodobenzylguanidine (MIBG) (no-carrier added)
Description: 124I-MIBG (no-carrier added) Administration (infusion, 1-2 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (no-carrier added) Administration \& PET/CT scan 6 weeks later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 124I-MIBG (carrier added)
Description: 124I-MIBG (carrier added) Administration (infusion, 60 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (carrier added) Administration \& PET/CT scan 6 weeks later.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) /Computerized tomography (CT)
Description: A PET scan measures important body functions, such as metabolism. CT imaging uses special x-ray equipment, and in some cases a contrast material, to produce multiple images of the inside of the body. Combined PET/CT scans combine the processes of both a PET and CT at the same time.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) /Computerized tomography (CT)
Description: A PET scan measures important body functions, such as metabolism. CT imaging uses special x-ray equipment, and in some cases a contrast material, to produce multiple images of the inside of the body. Combined PET/CT scans combine the processes of both a PET and CT at the same time.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography (PET) /Computerized tomography (CT)
Description: A PET scan measures important body functions, such as metabolism. CT imaging uses special x-ray equipment, and in some cases a contrast material, to produce multiple images of the inside of the body. Combined PET/CT scans combine the processes of both a PET and CT at the same time.